论文部分内容阅读
目的探讨临床应用基因重组人生长激素(r-hGH)治疗肝硬化失代偿期低蛋白血症的疗效。方法将66例肝硬化失代偿期合并低蛋白血症的患者随机分为两组,治疗组36例应用r-hGH,其他治疗同对照组,治疗前、治疗后第15、30天,治疗结束第30、60天检测两组患者肝功能和营养状况,观察24 h尿量及腹水的消退情况。结果治疗后治疗组血浆白蛋白明显增加,腹水消退明显,与对照组比较差异有统计学意义。结论 r-hGH可以提高肝硬化失代偿期合并低蛋白血症患者血清白蛋白水平,改善患者营养状况,无明显不良反应,具有临床应用价值。
Objective To investigate the clinical application of recombinant human growth hormone (r-hGH) in the treatment of decompensated cirrhosis and hypoproteinemia. Methods Sixty-six patients with decompensated cirrhosis and hypoproteinemia were randomly divided into two groups. The treatment group received 36 cases of r-hGH, the other treatment groups were the same as the control group. Before treatment, on the 15th and 30th days after treatment, At the end of the 30th and 60th days, the liver function and nutritional status of the two groups were detected. The urine output and the regression of ascites were observed 24 hours later. Results After treatment, the plasma albumin of the treatment group was significantly increased, the ascites subsided obviously, and the difference was statistically significant compared with the control group. Conclusion r-hGH can improve the level of serum albumin in patients with decompensation of liver cirrhosis and hypoproteinemia, improve the nutritional status of patients without obvious adverse reactions, and has clinical value.